Shell Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Shell Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-18,603	Closed	-$430K	–	1461
2020 Q4	$430K	Hold	18,603	–	–	0.01%	865
2020 Q3	$263K	Hold	18,603	–	–	0.01%	953
2020 Q2	$281K	Sell	18,603 -223	-1%	-$2.72K	0.01%	922
2020 Q1	$174K	Sell	18,826 -286	-1%	-$2.72K	﹤0.01%	1039
2019 Q4	$186K	Sell	19,112 -435	-2%	-$3.98K	﹤0.01%	1139
2019 Q3	$157K	Sell	19,547 -168	-0.9%	-$1.82K	﹤0.01%	1163
2019 Q2	$246K	Sell	19,715 -450	-2%	-$5.71K	0.01%	1082
2019 Q1	$274K	Hold	20,165	–	–	0.01%	1056
2018 Q4	$193K	Sell	20,165 -1,700	-8%	-$18.7K	﹤0.01%	1041
2018 Q3	$264K	Buy	+21,865	New	+$306K	0.01%	1081

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Shell Asset Management's FOLD Position: Q1 2021 in Review

Shell Asset Management sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 18,603 shares — an estimated $430K sold.

Shell Asset Management first reported a position in FOLD in Q3 2018 and held it in 10 quarters. The position peaked at $430K in Q4 2020. 258 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

Shell Asset Management reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
Shell Asset Management sold 18,603 Amicus Therapeutics shares in Q1 2021, an estimated $430K.
Shell Asset Management first reported a position in Amicus Therapeutics in Q3 2018 and held it in 10 quarters.
Shell Asset Management's Amicus Therapeutics position peaked at $430K in Q4 2020.
258 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Shell Asset Management's 13F filing for Q1 2021, filed 10 May 2021.